The Longevity Podcast: Optimizing HealthSpan & MindSpan
Welcome to a new era of conversation—where artificial intelligence explores what it means to live longer and better. Created and guided by Dr. Trinh, The Longevity Podcast uses AI hosts to bring scientific discovery, health innovation, and human wisdom together. Through AI-driven discussions inspired by real research and medical insight, each episode reveals practical tools for optimizing your healthspan and mindspan—rooted in science, shaped by compassion.
Mind. Body. Spirit.
Powered by Science, Guided by Humanity.
The Longevity Podcast: Optimizing HealthSpan & MindSpan
The New Alzheimer’s Timeline And The Tests That Catch It Early
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
You can “pass” a memory test and still reveal something chilling: your brain can confidently invent a word that was never said. We start there because that tiny intrusion error, caught by the right kind of neuropsychological scoring, may be one of the earliest objective signals of Alzheimer’s disease long before you lose your keys or miss an appointment.
We unpack a 2026 narrative review that argues Alzheimer’s isn’t a sudden drop from healthy to sick, but a decades-long biological process. The centerpiece is Objectively Defined Subtle Cognitive Decline (ObjSCD), a new stage between cognitively normal aging and mild cognitive impairment. We explain the actuarial criteria behind it, why “process scores” matter as much as total scores on tests like the Ray Auditory Verbal Learning Test, and how longitudinal ADNI data links these subtle patterns to higher rates of progression to MCI and dementia. We also dig into the compounding role of type 2 diabetes, showing how metabolic and inflammatory stress can accelerate decline.
Then we go under the hood with the ATN framework and modern biomarkers: amyloid PET findings, tau biology, early structural changes like entorhinal cortex thinning, white matter damage, and the surprising spike in cerebral blood flow that suggests the brain is compensating before it collapses. We close with what could make early detection scalable: blood-based biomarkers such as p-tau217 and NfL paired with short digital cognitive screens, plus the hard equity question of building algorithms on narrow datasets.
If a simple blood draw and a 10-minute iPad test could predict Alzheimer’s risk decades early, would you want to know? Subscribe, share this with someone who thinks about brain health, and leave a review with your answer.
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
A Memory Test That Traps You
SPEAKER_00Imagine for a second that you're sitting in a well, just a completely sterile, quiet clinic room.
SPEAKER_01Right. Just a classic doctor's office vibe.
SPEAKER_00Exactly. And a doctor is sitting across from you and they read a list of 15 totally random words out loud. Like uh drum, curtain bell, coffee, school.
SPEAKER_01Just standard vocabulary.
SPEAKER_00Yeah. And you nod along, you're feeling confident. When they finish, they ask you to repeat as many as you can remember.
SPEAKER_01Which is harder than it sounds, honestly.
SPEAKER_00It is. But you rattle off 10 of them easily. The doctor smiles, you feel great, you know, you pass the test. Right. But what you don't know, what the doctor is actually writing down on their clipboard, is that one of the words you just confidently recite it, let's just say it was the word window. It was never on the list.
SPEAKER_01Yes. You didn't just forget a word.
SPEAKER_00No. Your brain actively fabricated a completely false memory right on the spot.
SPEAKER_01And um, according to the newest research, that tiny, like imperceptible glitch, that momentary fabrication, it might actually be the very first invisible whisper of Alzheimer's disease.
SPEAKER_00Which is terrifying.
SPEAKER_01It really is. Because it's occurring potentially decades before you ever actually, you know, forget where you left your keys. Trevor Burrus, Jr.
SPEAKER_00Decades. So welcome to this deep dive, everyone. Today we are mapping the invisible frontier of Alzheimer's disease.
SPEAKER_01Aaron Powell It's a huge topic.
SPEAKER_00Massive. Because for a very long time, society has treated cognitive decline like well, like falling off a cliff.
SPEAKER_01Aaron Powell Yeah. The old healthy versus sick binary.
SPEAKER_00Exactly. You are perfectly fine, completely healthy, and then suddenly you just cross this invisible line and boom, you have dementia.
SPEAKER_01Aaron Powell But we are discovering that it isn't a cliff at all.
SPEAKER_00No, it's not. It's a very long, incredibly subtle slope.
SPEAKER_01Aaron Ross Powell And we are witnessing a I mean, it's really a massive conceptual earthquake in neurology right now.
SPEAKER_00Aaron Ross Powell An earthquake. I like that.
SPEAKER_01Aaron Ross Powell Yeah, because the field is just completely shifting away from treating Alzheimer's as a sudden event. Right. Instead, they're recognizing it as a prolonged, insidious, basically decades-long biological process.
SPEAKER_00Aaron Powell So to explore this, we are unpacking a truly fascinating stack of research today.
SPEAKER_01Some really cutting-edge stuff.
SPEAKER_00Absolutely. Our primary compass is a 2026 narrative review, and this was published in the Journal of Prevention of Alzheimer's disease.
SPEAKER_01That's a major publication in the field.
SPEAKER_00It is. And this work was spearheaded by Amanda the Lick Gonzalez, alongside just this powerhouse team of researchers bridging Boston University, Harvard Medical School, and the Universidad de Antioquia.
SPEAKER_01Yeah, that collaboration is, I mean, it brings together some of the sharpest minds in neurocognitive aging.
SPEAKER_00For sure.
SPEAKER_01And the review they put together essentially redefines how we classify the health of the human brain.
SPEAKER_00So the mission for our deep dive today is to explore a groundbreaking new diagnostic classification they detail in the paper, which is called Objectively Defined Subtle Cognitive Decline.
SPEAKER_01A bit of a mouthful.
SPEAKER_00It is a mouthful, so we'll just call it UbjSCD for short.
SPEAKER_01Perfect.
SPEAKER_00We're going to dig into exactly how scientists are learning to detect these microscopic fractures in our memory.
SPEAKER_01And crucially, we are going to talk about why this matters right this very second.
SPEAKER_00Right. Because we are officially living in the era of FDA-approved disease modifying treatments.
SPEAKER_01Which is huge. The urgency just cannot be overstated here.
SPEAKER_00Because we finally have the drugs, right?
SPEAKER_01Exactly. The medical community finally possesses tools and medications that might actually slow down the progression of this disease.
SPEAKER_00But there is a massive catch.
SPEAKER_01Always a catch. They're only effective if we know exactly when to deploy them.
SPEAKER_00Right. If we wait until the symptoms are obvious, the window for intervention is already slammed shut.
SPEAKER_01The damage is done at that point.
SPEAKER_00So whether you have a family history of cognitive issues that, you know, keeps you up at night, which so many people do. Or you're deeply fascinated by the mechanics of the human brain, or you just want to know what is happening at the absolute bleeding edge of health science, this deep dive is going to fundamentally rewire how you view memory.
SPEAKER_01That aging. Yeah. And really the silent machinery operating inside your own head.
SPEAKER_00So to even begin grasping this new frontier, we have to completely discard the old way of thinking about disease, don't we?
SPEAKER_01We really do. I mean, we love binary categorizations as humans, healthy versus sick, broken versus not broken.
SPEAKER_00It's just easier to process.
SPEAKER_01It is. But when you step into the world of neurodegeneration, that binary framework just completely collapses.
SPEAKER_00Okay, let's build the new map then. If it isn't healthy versus sick, what does the actual timeline of Alzheimer's look like to a
Alzheimer’s As A Long Slope
SPEAKER_00neurologist today?
SPEAKER_01So we operate on something called the Alzheimer's disease continuum.
SPEAKER_00The continuum.
SPEAKER_01Yeah. Okay. And historically, clinical practice divided this continuum into three very distinct, easily digestible phases.
SPEAKER_00Let's walk through those. What's phase one?
SPEAKER_01The first phase is cognitively normal or CN.
SPEAKER_00CN, got it.
SPEAKER_01And this is exactly what it sounds like. You're functioning precisely as expected for someone of your age and your educational background.
SPEAKER_00So my memory is fine, I can plan my day, all that.
SPEAKER_01Exactly. Your memory is intact, your executive function is sharp, and you just navigate the world without issue.
SPEAKER_00Okay, that's the baseline we all obviously hope to stay in. What's the next step down?
SPEAKER_01The second phase is known as mild cognitive impairment or MCI.
SPEAKER_00MCI. You hear that acronym a lot.
SPEAKER_01You do. Yeah. Because in this stage, there's a noticeable, objectively measurable decline in cognitive abilities.
SPEAKER_00Like what specifically?
SPEAKER_01We are talking about memory, language, spatial awareness. It's significant enough that a doctor can actually measure the deficit on a standard test.
SPEAKER_00Okay.
SPEAKER_01And usually the patient or their family actually notices it happening.
SPEAKER_00But they're not completely incapacitated.
SPEAKER_01Right. And that is the key distinction. The impairment is not severe enough to strip away their independence.
SPEAKER_00Okay, so they might um struggle to find a specific word or something.
SPEAKER_01Yeah, or they might lose their train of thought more often, but they are still driving, they're paying their bills, they're managing their daily lives.
SPEAKER_00And then the final phase is when that independence is lost.
SPEAKER_01Precisely. The third phase is full dementia.
SPEAKER_00Right.
SPEAKER_01This is the stage where the cognitive impairments have become so severe and so widespread that they actively interfere with independent living.
SPEAKER_00So they need full-time care at this point.
SPEAKER_01Yeah. The patient requires significant assistance with basic daily activities. And for decades, that was the gold standard map, right? Normal, the MCI, then dementia.
SPEAKER_00But reading through the source material, that three-stage map feels honestly incredibly flawed.
SPEAKER_01Oh, it's hugely flawed.
SPEAKER_00The massive glaring problem is the jump from normal to MCI. The paper emphasizes that by the time someone is officially diagnosed with mild cognitive impairment, colossal biological changes have already taken place inside their skull.
SPEAKER_01Massive changes.
SPEAKER_00If we use an analogy of a house, by the time MCI sets in, the foundation is cracked, the walls are smoking, and the roof is about to cave in.
SPEAKER_01That's a great way to put it. The structural integrity of the brain has already been severely compromised.
SPEAKER_00Just totally ravaged.
SPEAKER_01Yeah. Toxic proteins have likely been silently pooling in the brain for 10, 15, or even 20 years before that MCI diagnosis is ever handed down.
SPEAKER_0020 years. Which means if we wait for MCI to prescribe these new FD-approved drugs, we are showing up to the house fire with a garden hose. The damage is irreversible.
SPEAKER_01That is the exact clinical dilemma driving this whole field of research right now.
SPEAKER_00We need a better smoke detector.
SPEAKER_01Exactly. If we want to actually change the trajectory of the disease, we have to push our diagnostic window way far to the left on that timeline.
SPEAKER_00We have to look at the space before MCI.
SPEAKER_01Yes. And that brings us to the centerpiece of the review, which is objectively defined subtle cognitive decline.
The Old Three-Stage Model
SPEAKER_00Abjay S C D. Let's really define this invisible middle ground.
SPEAKER_01So AbjayScd represents a highly specific preclinical stage. It is a newly carved out territory between being totally cognitively normal and having mild cognitive impairment.
SPEAKER_00So it's right in that gray area.
SPEAKER_01Exactly. In this phase, an individual is exhibiting minimal cognitive difficulties.
SPEAKER_00But they wouldn't trigger an MCI diagnosis.
SPEAKER_01No, they do not meet the clinical criteria for MCI. They are certainly not experiencing dementia.
SPEAKER_00Right.
SPEAKER_01But the objective data shows they are no longer operating at their normal baseline either.
SPEAKER_00Let's try to visualize this. It's kind of like an air conditioning unit in a house with a broken window.
SPEAKER_01Well, I like this. Go on.
SPEAKER_00So to you, standing in the living room, the temperature feels perfectly fine. You don't think there is a problem at all?
SPEAKER_01Because the AC is keeping up.
SPEAKER_00Right. But if you were to hook a diagnostic meter up to the AC unit itself outside, you would see that the motor is blasting at 110% capacity.
SPEAKER_01It's working overtime.
SPEAKER_00Yeah. It's drawing massive amounts of excess power just to maintain that baseline temperature.
SPEAKER_01Exactly.
SPEAKER_00So it looks like it's working fine on the surface, but the machinery is under intense strain and it is going to eventually burn out.
SPEAKER_01That is a brilliant way to frame it. With MCI, the EC unit is already burned out and the house is getting hot.
SPEAKER_00Right. The symptoms are obvious.
SPEAKER_01But with FJGS CD, the room is still cool, you don't feel it. But the diagnostic meter is screaming that something is wrong.
SPEAKER_00So the challenge for neurologists has basically been figuring out how to build a meter sensitive enough to read that strain.
SPEAKER_01That's exactly it.
SPEAKER_00So how do you do that? How do you mathematically prove that someone's brain is secretly working in overdrive if they seem completely fine to everyone around them?
SPEAKER_01Well, the review heavily focuses on what they call the Edmonds and Thomas actuarial criteria.
SPEAKER_00Actuarial criteria? Sounds like life insurance math.
SPEAKER_01It kind of is. This is where the diagnosis becomes purely mathematical. It relies on objective data rather than just a doctor's subjective opinion of how the patient seems.
SPEAKER_00Okay, so what's the math?
SPEAKER_01To be classified with UBJSCD, you must perform poorly on very specific, highly calibrated neuropsychological tests.
SPEAKER_00How poorly?
SPEAKER_01The mathematical threshold is that your score must fall more than one standard deviation below the mean.
SPEAKER_00Okay, let me pause you there. Because we throw the term standard deviation around a lot, but what does that actually look like in practice for a patient?
SPEAKER_01Sure. Imagine a massive bell curve graph that plots the memory test scores of tens of thousands of people.
SPEAKER_00Okay, got the bell curve in my head.
SPEAKER_01The peak of that bell right smack in the middle is the average score. That's the mean.
SPEAKER_00Most people are bunched up right there.
SPEAKER_01Exactly. A standard deviation is just a statistical way of measuring how far away you are from that average middle peak. If you move one standard deviation to the left of the peak, so you're scoring lower, you are dropping below about 84% of the population.
SPEAKER_00Wow. Okay, so it's a significant drop. And crucially, the review notes that they don't just compare you to the general population.
SPEAKER_01Oh no, not at all. That wouldn't work.
SPEAKER_00They adjust that bell curve specifically for you.
SPEAKER_01Yes, that is vital. The normative data is rigorously adjusted for your age, your years of formal education, and your sex.
SPEAKER_00Because a 20-year-old and an 80-year-old shouldn't be on the same curve.
SPEAKER_01Exactly. A 45-year-old software engineer with a master's degree is compared strictly against a massive database of other 45-year-old people with master's degrees.
SPEAKER_00Okay, that makes total sense.
SPEAKER_01If you drop one standard deviation below your specific peer group, that's when the mathematical alarm bells start ringing.
SPEAKER_00So how does this actuarial math actually define Ub J SED? The source material mentions it was built on top of an older system called the uh the Jack Bondi MCI criteria.
SPEAKER_01Right, the Jack Bondi criteria. So under that older system for diagnosing full mild cognitive impairment, a patient generally needs to score below expectations on two separate tests within a single cognitive domain.
SPEAKER_00Wait, what's a domain?
SPEAKER_01Like memory or language or spatial reasoning.
SPEAKER_00Okay, so they bomb two different memory tests, they get the MCI diagnosis.
SPEAKER_01Exactly. Of JSCD scales that threshold back to catch the decline much earlier before two full tests in one domain are completely failed.
SPEAKER_00So they're lowering the bar to catch the subtle slips.
SPEAKER_01Yes. The review lays out three very specific mathematical pathways to get flagged with an abj-cD classification.
SPEAKER_00Okay, walk us through them. What's pathway one?
SPEAKER_01The first pathway is categorized as late abj SED.
SPEAKER_00Late, meaning closer to MCI.
SPEAKER_01Yes. This occurs when a patient has one impaired total test score in two different cognitive domains.
SPEAKER_00Okay, give me an example.
SPEAKER_01So for instance, their memory score dips below that one standard deviation mark, but not enough to fail two tests. And then their executive function score also dips below that mark on a different test. Neither domain is fully impaired enough to trigger an MCI diagnosis on its own, but they were slipping slightly across multiple areas.
SPEAKER_00The structural integrity is wavering in a few different places in the house, but nothing has totally collapsed yet.
SPEAKER_01Precisely. You're seeing cracks in different rooms.
SPEAKER_00Okay, what's the next pathway?
SPEAKER_01The second pathway is designated as early abjage SCD.
Why MCI Is Too Late
SPEAKER_01And this is where the science gets incredibly granular.
SPEAKER_00Okay, I'm ready.
SPEAKER_01A patient falls into this category if they have two impaired neuropsychological process scores.
SPEAKER_00Okay. This was the most fascinating part of the review for me. The distinction between a total score and a process score.
SPEAKER_01It really is brilliant.
SPEAKER_00It feels like the secret decoder ring for early Alzheimer's. Let's break this down. What is the difference between those two scores?
SPEAKER_01It is basically the difference between measuring the final destination versus analyzing the journey taken to get there.
SPEAKER_00Oh, I like that.
SPEAKER_01Let's look at the Ray Auditory Verbal Learning Test, or the AVLT, which is the cornerstone assessment used in much of this research.
SPEAKER_00That's the 15 words test we talked about in the intro.
SPEAKER_01Exactly. The administrator reads a list of 15 words. A total score is simply the final tally of your recall capacity. You remember 10 out of 15 words.
SPEAKER_00So it's purely quantitative, just a number.
SPEAKER_01Right. It just tells us how much data the brain held on to. But a process score is entirely qualitative.
SPEAKER_00Qualitative? How so?
SPEAKER_01It analyzes the mechanics of how you took the test. It looks at your cognitive approach, your strategies, and the specific architecture of your errors.
SPEAKER_00This goes back to the scenario at the very beginning of our deep dive, the intrusion error.
SPEAKER_01Exactly. An intrusion error is a classic process metric.
SPEAKER_00Walk us through it again, just to be clear.
SPEAKER_01If the doctor reads drum, curtain, bell, later you confidently say window, your total score might still look perfectly fine because you remembered enough correct words to stay above the cutoff threshold.
SPEAKER_00Right. You got 10 out of 15, you passed.
SPEAKER_01Yes. But the process score catches the fact that your brain's source monitoring failed. Your brain actively generated a false memory and presented it to you as reality.
SPEAKER_00I want to linger on why that happens biologically. Because it's so weird. Why does the brain invent a word?
SPEAKER_01It often comes down to a breakdown in semantic clustering and source memory.
SPEAKER_00Semantic clustering, that sounds like a filing system.
SPEAKER_01It is. A healthy brain organizes information efficiently. It clusters words by category. If I say apple and banana, you file them under fruit.
SPEAKER_00Okay.
SPEAKER_01But as the subtle pathology of Alzheimer's begins to interfere with the hippocampus and the frontal lobes, the brain struggles to accurately tag where a piece of information actually came from.
SPEAKER_00Ah, so it loses the tag.
SPEAKER_01Right. So it might pull a word related to the list's general theme from your long-term memory, fail to verify that the doctor actually said it out loud just now, and offer it up as an answer.
SPEAKER_00The filing system is starting to mislabel the folders.
SPEAKER_01Exactly.
SPEAKER_00And so returning to the pathways, pathway two for early of JS CD is having two of these impaired process scores. So your total memory capacity might still be totally normal. You are remembering enough words, but the mechanical way your brain is retrieving them is glitching.
SPEAKER_01Yes. The underlying circuitry is fraying. And just for thoroughness, the third pathway to an obj SCD classification is a hybrid. Which is having one impaired total score combined with one impaired process score.
SPEAKER_00Okay, so we have this really elegant mathematical model. If your scores dip in these very specific ways, you get placed in the object SCD bucket. Correct. But a bucket is just a bucket unless it actually holds water, right? The burning question is does this classification actually predict anything real?
SPEAKER_01Right. Does it matter?
SPEAKER_00Yeah. If I make a couple of intrusion errors on a word test, does that actually mean I am on a high-speed train toward Alzheimer's disease?
SPEAKER_01Well, to validate this model, the researchers couldn't just look at a snapshot in time. They had to follow patients for years to see what happened to them.
SPEAKER_00You need longitudinal data.
SPEAKER_01Exactly. So Thomas and colleagues utilize data from the Alzheimer's Disease Neuroimaging Initiative, or ADNI.
SPEAKER_00Before we hit the stats on that, we need to talk about ADNI. Because this acronym pops up constantly in neurological research. What actually is it?
SPEAKER_01ADI is arguably one of the most important scientific endeavors in the history of Alzheimer's research.
SPEAKER_00Wow, really?
SPEAKER_01Oh yeah. It was launched back in 2004, funded by the National Institutes of Health, alongside private pharmaceutical companies.
SPEAKER_00Okay, so big money behind it.
SPEAKER_01Massive. It is a huge, multi-center longitudinal study. The goal was to recruit hundreds of adults, some perfectly healthy, some with MCI, some with early Alzheimer's, and just track them relentlessly over time.
SPEAKER_00Tracking them how? Like what are they measuring?
SPEAKER_01They gather everything you can imagine: MRI scans, PT scans, blood draws, spinal fluid, and incredibly rigorous cognitive testing year after year.
SPEAKER_00So they're just building this massive database.
SPEAKER_01Essentially, they created a unified open source database of brain aging. It allowed researchers anywhere in the world to download this massive set of standardized data to test their
Defining Objective Subtle Decline
SPEAKER_01theories.
SPEAKER_00Oh, that's amazing. So it's the ultimate gold standard testing ground. And when the researchers applied the UBJ SCD mathematical criteria to this historical ADNI data, what did they find? Let's look at the five-year progression to mild cognitive impairment.
SPEAKER_01The predictive power is staggering, honestly. Let's look at the baseline first.
SPEAKER_00Okay.
SPEAKER_01For individuals in the database who are classified as normal controls, over a five-year period, 31.4% of them progress to MCI.
SPEAKER_00Which makes sense. I mean, the population is aging and cognitive decline happens naturally to a certain degree. The people who just had those process score glitches, the intrusion errors.
SPEAKER_01Right. Within that exact same five-year window, 60.8% of them progressed to clinical MCI.
SPEAKER_00Whoa. The risk virtually doubles based on how they took a word test five years prior?
SPEAKER_01Yes. And it accelerates further. For the late subtle cognitive decline group, the LSCD group.
SPEAKER_00Those with the slight BIPs across multiple domains.
SPEAKER_01Exactly. 72.6% of them progressed to MCI within five years.
SPEAKER_00Man, nearly three out of every four people in that category suffered a major clinical decline.
SPEAKER_01It's a massive jump. And the numbers regarding the progression to full dementia are equally compelling.
SPEAKER_00Okay, give us those.
SPEAKER_01Over that same five-year span, normal controls progressed to dementia at a rate of just 4.2%.
SPEAKER_00Okay, so a relatively low risk over a half decade for a normal person.
SPEAKER_01But the ESCD group progressed to dementia at 11.9%, and the LSCD group at 14.2%.
SPEAKER_00So the review explicitly states that people with obj SCD progress to MCI 2.5 to 3.4 times
The Actuarial Math Behind Diagnosis
SPEAKER_00faster than normal participants.
SPEAKER_01That's math.
SPEAKER_00This completely validates the AC Broken Window metaphor. The math works. The actuarial criteria are successfully detecting the invisible strain on the system years before it breaks.
SPEAKER_01It's an incredibly powerful predictive tool. And what makes it even more vital is how it interacts with other health factors.
SPEAKER_00What do you mean, like comorbidities?
SPEAKER_01Yes. The review highlights a study by Thomas et al. exploring the compounding effect of type 2 diabetes on this subtle decline.
SPEAKER_00Now, I really want to dive deep into this. We generally think of diabetes as a blood sugar issue affecting the body, you know, maybe the heart or the kidneys or circulation. Why is it accelerating cognitive decline?
SPEAKER_01It comes down to a concept that many researchers refer to informally as type 3 diabetes.
SPEAKER_00Type 3 diabetes, I've never heard that.
SPEAKER_01It's gaining a lot of traction. So the brain is an absolute energy hog. It requires a massive constant supply of glucose to fuel the neurons and maintain neuroplasticity.
SPEAKER_00Right. It runs on sugar, basically.
SPEAKER_01Exactly. And just like the rest of the body, the brain relies on insulin to process that glucose.
SPEAKER_00Okay. So what happens when someone has type 2 diabetes and their body becomes insulin resistant?
SPEAKER_01Well, the brain cells themselves can become insulin resistant.
SPEAKER_00Wait, really? The neurons?
SPEAKER_01Yes. The receptors on the neurons stop responding effectively to insulin. So even if there is plenty of glucose in the bloodstream, the brain cells literally begin to starve because they can't absorb it.
SPEAKER_00Oh wow. So they're swimming in food, but they're starving to death.
SPEAKER_01Precisely. On top of that, type 2 diabetes causes chronic systemic inflammation throughout the whole body.
SPEAKER_00And that hits the brain too.
SPEAKER_01Oh, absolutely. This inflammation acts like sandpaper and the blood-brain barrier. It degrades its integrity and allows harmful toxins to cross into the brain tissue, which just accelerates the neurodegenerative process.
SPEAKER_00So if you take a brain that is already in the UJ SCD phase, you know, already struggling with early Alzheimer's pathology, and you add the starvation and the inflammation of diabetes on top of it.
SPEAKER_01It's like throwing gasoline on an ember.
SPEAKER_00God, that's a devastating combo.
SPEAKER_01It really is. The researchers found that individuals who had both type 2 diabetes and an UBJ S C D classification showed a profoundly faster rate of functional decline over five years compared to those who only had one risk factor or neither.
SPEAKER_00It's a devastating Synergy. Now, I have to push back here for a moment just on the data itself.
SPEAKER_01Sure, go for it.
SPEAKER_00Because this all sounds incredibly airtight, but it's heavily reliant on the ADNI data set, right?
SPEAKER_01It is.
SPEAKER_00And as massive and important as ADNI is, isn't it a notoriously narrow slice of humanity?
SPEAKER_01Aaron Powell It is a critical limitation, and you're right to point it out. The review authors are very transparent about it.
SPEAKER_00Aaron Powell Because who is actually in that database?
SPEAKER_01Aaron Powell The ADI cohort is largely composed of highly educated, predominantly white individuals from specific, usually higher socioeconomic backgrounds.
SPEAKER_00Trevor Burrus, which does not represent the whole world.
SPEAKER_01Aaron Powell Not even close. It does not accurately reflect the vast genetic, cultural, and educational diversity of the global population.
SPEAKER_00Aaron Powell And beyond just the demographics, they are using a very specific set of tests in ADNI, right?
SPEAKER_01Yes. The JJCD math relies heavily on the Ray AVLT for those crucial process scores we talked about.
SPEAKER_00Aaron Powell So the 15 words test.
SPEAKER_01Right. But we don't know for certain if these exact actuarial formulas would hold up if a doctor in a different country used a completely different memory assessment translated into another language.
SPEAKER_00Right. Because cultural context matters in memory.
SPEAKER_01Absolutely. If the test changes, does the math still catch the decline? We just don't know. We urgently need diverse global data sets to stress test these criteria before they can become a universal clinical standard.
SPEAKER_00Okay, so the theory is incredibly strong, but it needs to be proven outside the vacuum of the ADNI bubble?
SPEAKER_01Exactly.
SPEAKER_00But let's follow the evidence we do have to the next logical step. We've established that failing these subtle process tests predicts clinical decline, but behavioral tests are just observing the outside of the machine, right?
SPEAKER_01Yes, it's just behavior.
SPEAKER_00To truly prove UBJSCD is a biological reality, we need to open the skull and look at the tissue. Does a bad score on a word test actually correlate with physical toxic damage inside the brain?
SPEAKER_01To answer that, the researchers shifted their focus from pen and paper tests to advanced neuroimaging. They map the UBSCD group against the ATN framework.
SPEAKER_00The ATN framework. ATN. We really need to define this because it is essentially the rosetta stone from modern Alzheimer's research. Let's start with A.
SPEAKER_01Okay, so A stands for amyloid beta.
SPEAKER_00What is that exactly?
SPEAKER_01These are protein fragments that occur normally in the brain. But in Alzheimer's disease, they misfold, they become sticky, and they clump together to form these hard plaques in the spaces between the nerve cells.
SPEAKER_00Just gumming up the works.
SPEAKER_01Exactly. These plaques disrupt cell function and they trigger inflammation.
SPEAKER_00So if object SCD is a true preclinical stage of Alzheimer's, we should see these amyloid plaques actively forming in these patients. What did the scans actually reveal?
SPEAKER_01Well, Thomas et al. tracked amyloid accumulation over a 48-month period using PD scans. Oh. They discovered that individuals mathematically classified as having objects CD had a significantly faster rate of amyloid beta accumulation compared to cognitively normal individuals.
SPEAKER_00So the toxic garbage is piling up faster.
SPEAKER_01Much faster. Furthermore, they found that the object SCD group represents a true transitional stage in terms of total amyloid burden.
SPEAKER_00Transitional how?
SPEAKER_01The prevalence of people who were amyloid positive in the Apig SCD group was higher than in normal individuals, but it was lower than in those who had already reached full MCI.
SPEAKER_00Ah, so it really is the missing link.
SPEAKER_01It is the missing biological link. It captures the disease in the active act of depositing the plaques right before it reaches the critical threshold that triggers obvious daily impairment.
SPEAKER_00Which brings us to perhaps the most fascinating and frankly the most existentially terrifying part of this entire review.
SPEAKER_01I know exactly what you're gonna say.
SPEAKER_00The debate between objective truth and subjective reality.
SPEAKER_01Yes. This is where the psychology of the disease intersects directly with the biology.
SPEAKER_00Because look, we've all had that moment of panic. You open the refrigerator, you stare blankly at the shelves, and you have absolutely no idea what you came to get.
SPEAKER_01Or you walk into a room and forget why you're there.
SPEAKER_00Exactly. Or you are at a party and you completely blank on the name of someone you've known for five years.
SPEAKER_01It's the worst.
SPEAKER_00It is a terrible feeling, and your immediate thought is always, is this it? Is my memory going? Do I have early Alzheimer's?
SPEAKER_01It's a very common fear.
SPEAKER_00So how does the mathematical objective diagnosis of UBJ S C D compare to people who simply feel like their memory is failing?
SPEAKER_01Well, the researchers analyzed a study by Wren et al. that directly compared UJSCD to a category called subjective cognitive decline or SCD.
SPEAKER_00Okay, what exactly constitutes SCD?
SPEAKER_01Subjective cognitive decline is when a patient goes to their doctor and actively complains, my memory is getting worse. I feel like I'm slipping.
SPEAKER_00Okay, so they're self-reporting a problem.
SPEAKER_01Right. But when the doctor administers standard cognitive tests, the patient's
Total Score Versus Process Errors
SPEAKER_01scores are totally normal.
SPEAKER_00They pass the tests fine.
SPEAKER_01Yes. The patient feels the decline, but the objective tools can't measure it.
SPEAKER_00So they took the people who complained but tested fine and compared them to the objust CD group, the people who might not be complaining but mathematically failed the subtle process scores. What did their brains look like?
SPEAKER_01The imaging results were undeniable. The individuals with objectively defined objus CD had significantly greater amyloid beta burden, heavily clustered in their frontal and temporal lobes compared to the normal group.
SPEAKER_00Okay, so the obj S CD folks have the plaques.
SPEAKER_01But here's the critical part. They also had significantly more amyloid than the subjective cognitive decline group.
SPEAKER_00Wait, let me make sure I'm hearing this right. The people who went to the doctor, actively worried and complaining that they were losing their memory, didn't actually have more toxic plaques than a normal, healthy person.
SPEAKER_01Correct. The study found that individuals with subjective cognitive decline did not differ from normal controls in terms of amyloid deposition.
SPEAKER_00That is wild.
SPEAKER_01It really challenges how we think about self-reporting.
SPEAKER_00So feeling like you are losing your memory doesn't necessarily mean the Alzheimer's pathology has actually started, but failing a math-based process score does.
SPEAKER_01And it gets even deeper, honestly, when we look at the T in the ATN framework.
SPEAKER_00Okay, so A is amyloid. T stands for Tau. Let's pause and define what Tau is mechanically, because it behaves very differently than amyloid, right?
SPEAKER_01Yes, it's a completely different mechanism of destruction. How so? While amyloid forms plaques outside the cells, in the spaces between them, tau destroys the cells from the inside.
SPEAKER_00Oh wow.
SPEAKER_01In a healthy neuron, tau proteins act like railroad ties. They stabilize these little microtubule tracts that transport nutrients up and down the cell.
SPEAKER_00Like the internal logistics network.
SPEAKER_01Exactly. But in Alzheimer's, these tau proteins become defective. They detach from the microtubules and they stick to one another, forming these tangled threads inside the neuron.
SPEAKER_00The tangles.
SPEAKER_01Yes, neurofibrillary tangles. And when that happens, the transport system collapses and the cell essentially starves to death.
SPEAKER_00Aaron Ross Powell It chokes the cell from the inside out. That is brutal. So how does this internal tangling relate to the subjective complainers versus the objective test takers?
SPEAKER_01Aaron Powell So a separate study by Thomas et al. mapped out tau accumulation against subjective memory complaints or SMC.
SPEAKER_00Okay.
SPEAKER_01They created a matrix. They looked at people who complained versus people who didn't complain and cross-referenced them with people who had obj SED and people who didn't.
SPEAKER_00So four different groups in this matrix. What was the standout data point?
SPEAKER_01The group that exhibited the absolute highest, most severe burden of toxic tau tangles in their brains was the group that was SMC negative.
SPEAKER_00Wait, SMC negative, meaning that they didn't complain.
SPEAKER_01Meaning they explicitly and constantly stated they did not think they had any memory problems whatsoever.
SPEAKER_00But they were in the obj SCD group.
SPEAKER_01Yes. They were SMC negative, but obj SCD positive.
SPEAKER_00That is staggering. The people with the most physical destruction occurring inside their brain cells were the ones who mathematically failed the subtle test but consciously believed their memory was absolutely fine.
SPEAKER_01Yes. They completely lacked insight into their own cognitive decline.
SPEAKER_00That is I mean, that's terrifying.
SPEAKER_01In later stages of Alzheimer's, this phenomenon is really well documented. It's known as anasognosia.
SPEAKER_00Anasognosia. The inability to perceive your own illness.
SPEAKER_01Exactly. The disease damages the very networks in the brain required for self-awareness and self-monitoring. But what this data reveals is that this profound lack of awareness is happening incredibly early in the disease process.
SPEAKER_00It is philosophically horrifying. The disease doesn't just destroy your memories, it actively unplugs your biological alarm system so you don't realize the memories are burning in the first place.
SPEAKER_01That's a great way to put it. The brain's lack of awareness is actually a primary symptom of the pathology itself.
SPEAKER_00Which perfectly illustrates why modern neurology just cannot rely on patient self-reporting for early detection.
SPEAKER_01Aaron Powell Right, because the pathology actively masks itself from the patient's conscious mind. We have to use the actuarial criteria of obj SCD to pierce through that illusion and see the biological truth.
SPEAKER_00Okay, so the ATN framework shows us that A, the amyloid plaques, and T, the tau tangles, are relentlessly accumulating during the MJSCD phase, even if the patient is blissfully unaware. Right. That brings us to the end, neurodegeneration. If the chemical soup is toxic, what is it doing to the physical architecture of the brain?
SPEAKER_01Aaron Ross Powell Well, to measure neurodegeneration, researchers use structural MRI scans to track how the thickness and volume of different brain regions actually change over time.
SPEAKER_00Shrinkage, basically.
SPEAKER_01Yeah, exactly.
SPEAKER_00When we talk about Alzheimer's and brain volume, everyone immediately thinks of the hippocampus.
SPEAKER_01Always. It's the famous one.
SPEAKER_00The sea horse-shaped structure deep in the brain that acts as the primary hard drive for our memories. It famously shrinks as the disease progresses.
SPEAKER_01It does. But remember, Abjay S C D is designed to catch the disease very, very early.
SPEAKER_00Right.
SPEAKER_01So when researchers looked at the hippocampus in the AbjayS CD group over a 48-month period, they found something really surprising.
SPEAKER_00What was it?
SPEAKER_01It didn't show significant atrophy compared to cognitively normal individuals.
SPEAKER_00Wait, really? If they have toxic plaques and tangles actively building up in there, why isn't the memory center shrinking?
SPEAKER_01Because neurodegeneration operates as a domino effect. It follows the path of the amyloid and tau. Severe hippocampal atrophy is actually a relatively late stage event.
SPEAKER_00Okay.
SPEAKER_01It becomes visually prominent on a scan when the patient reaches MCI and dementia. The fact that the hippocampus is still structurally intact in the UBJSCD group proves that this mathematical classification is successfully capturing the disease before the major structural collapse occurs.
SPEAKER_00It's catching it in the preamble. Yes. So if the hippocampus isn't shrinking yet, what is? Where does the physical damage actually start?
SPEAKER_01The study found that participants with obj S C D showed faster thinning in the atorhinal cortex compared to normal controls.
SPEAKER_00The entorhynal cortex. Paint a picture of what that does for us.
SPEAKER_01Think of it as the main information highway, the central gateway leading directly into the hippocampus.
SPEAKER_00Okay.
SPEAKER_01It wrote sensory and spatial information into the memory center to be processed and stored. Alzheimer's pathology typically establishes its initial beachhead in the entorhyinal cortex before spreading deeper.
SPEAKER_00Oh, I see.
SPEAKER_01So the obj SED criteria are catching the disease exactly at that beachhead, right as the gateway begins to physically degrade, but before the hippocampus itself falls.
ADNI Data And Five-Year Risk
SPEAKER_00That is an incredible level of diagnostic precision. We're catching the invaders at the gates.
SPEAKER_01Literally.
SPEAKER_00But the brain isn't just gray matter, right? It's also a massive network of biological wiring. What is happening to the plumbing and the cables in this early stage?
SPEAKER_01Yeah, so the review dives into neurovascular alterations, specifically looking at white matter hyperintensities or WMHs.
SPEAKER_00Break down white matter for us. What's the difference between gray and white? Sure.
SPEAKER_01If the gray matter, like the cortex and the hippocampus we just talked about, are the computers doing the processing, the white matter represents the miles of insulated fiber optic cables connecting all those computers together.
SPEAKER_00Got it. It allows different brain regions to communicate.
SPEAKER_01Exactly. And white matter hyperintensities show up as these bright glowing spots on an MRI scan.
SPEAKER_00Which is bad.
SPEAKER_01Yes. They indicate areas where those cables have suffered tiny lesions or vascular damage, often due to poor blood flow.
SPEAKER_00Like the insulation fraying on a wire.
SPEAKER_01Exactly. A study by Calcettis et al. found that individuals with obj S C D had significantly greater volumes of these WMHs in their temporal, occipital, and frontal lobes compared to normal individuals.
SPEAKER_00So the communication infrastructure is already taking hits.
SPEAKER_01Yes. Though the review does offer a pretty big caveat on that specific finding.
SPEAKER_00Right. There was a genetic component they mentioned.
SPEAKER_01Yes. The authors point out that the obj S C D group in that study had a higher prevalence of the APOE epsilon-4 gene compared to the normal group. Which is exactly APOE Epsilon-4 is the strongest known genetic risk factor for late-onset Alzheimer's. But here's the thing it's also known to independently cause vascular issues.
SPEAKER_00Oh, I see. So it's difficult to untangle how much of that white matter damage is due directly to the obj SCD pathology versus just the underlying genetic predisposition causing bad plumbing.
SPEAKER_01It's a very tangled web. But speaking of vascular issues and plumbing, the data regarding cerebral blood flow completely blew my mind.
SPEAKER_00Let's get into that. Because logically, if the brain is accumulating toxic protein and the gray matter is thinning and the white matter cables are fraying, you would assume the whole system is just powering down.
SPEAKER_01Right, you'd expect less activity.
SPEAKER_00You'd expect to see a decrease in blood flow.
SPEAKER_01That is exactly what neurologists assumed for a long time. But the advanced imaging proved them wrong. Researchers used a technique called arterial spin labeling MRI.
SPEAKER_00Okay, arterial spin labeling, how does that actually work? How do you see blood flow on an MRI without injecting a contrast dye?
SPEAKER_01It's an incredibly elegant technique. The MRI machine uses radio frequency pulses to magnetically tag or label the water molecules in the arterial blood in the neck just before it enters the brain.
SPEAKER_00Whoa, it magnetizes the blood.
SPEAKER_01Essentially, yes. And as that tagged blood flows up into the brain tissue, the scanner measures it, allowing researchers to create a highly accurate, completely non-invasive map of regional cerebral blood flow.
SPEAKER_00That is so cool. Okay, so they mapped the blood flow of the UBJSCD patients. What did they find?
SPEAKER_01Thomas et Hall discovered that the UBJ SCD group actually exhibited increased cerebral blood flow in the hippocampus and the inferior parietal regions.
SPEAKER_00Increased.
SPEAKER_01Yes, compared to both normal controls and individuals with full MCI.
SPEAKER_00Wait, increased. The damaged brain is drawing more blood than a healthy brain.
SPEAKER_01Yes. Researchers refer to this as an inverted U-shaped pattern.
SPEAKER_00The inverted U.
SPEAKER_01Yeah. To use your air conditioner metaphor from earlier, this is the exact moment we see the motor blasting at 110%.
SPEAKER_00Ah, okay. I see it now.
SPEAKER_01In the normal stage, blood flow is at a stable baseline. But when the brain enters the JSCD stage, it begins to experience early metabolic stress and toxicity from the amyloid and tau.
SPEAKER_00It knows it's under attack.
SPEAKER_01Right. And in response, the brain's neurovascular system overcompensates. It frantically revs the engine, dilating vessels and pumping extra blood and oxygen to those vulnerable memory regions just to keep the cognitive lights on.
SPEAKER_00The brain is actively fighting back against the decline.
SPEAKER_01It's a desperate act of neurovascular compensation. But it is entirely unsustainable.
SPEAKER_00Right, because the motor eventually burns out.
SPEAKER_01Exactly. By the time the disease progresses to the MCI stage, that compensatory mechanism is totally exhausted, the vascular system gives out, and blood flow drops significantly. Trevor Burrus, Jr.
SPEAKER_00Forming the downward slope of that inverted U.S.
SPEAKER_01Precisely. The fact that the Ub JSCD criteria capture the brain at this precise moment of peak frantic conversation is just profound.
SPEAKER_00Aaron Powell We are literally photographing the brain in the middle of a war. It is destined to lose without intervention.
SPEAKER_01That's exactly what's happening.
SPEAKER_00And we can also see this frantic compensation in how the different brain networks are talking to each other, right? The functional MRI data.
SPEAKER_01Aaron Ross Powell Yes. The review looks at resting state fMRI.
SPEAKER_00How is fMRI different from a regular MRI?
SPEAKER_01Aaron Ross Powell Unlike a structural MRI that just takes a static picture of the anatomy. Like a photograph, an FMRI measures the Bold E signal. That stands for blood oxygen level dependent signal.
SPEAKER_00Okay.
SPEAKER_01It tracks where oxygenated blood is moving in real time while a patient is just resting in the scanner. This allows researchers to see which brain regions are functionally firing together and communicating in synchronized networks.
SPEAKER_00Like watching traffic patterns in a city.
SPEAKER_01Exactly.
SPEAKER_00So what happens to those traffic patterns in the UBJ SCD phase?
SPEAKER_01Well, a study by Cree et al. found that people with a Bay SED displayed unique functional connectivity patterns that were entirely distinct from those seen in amnestic MCI.
SPEAKER_00What kind of patterns?
SPEAKER_01Specifically, the obj SED group showed greater functional activity in the right middle occipital gyrus and less activity in the left percuneus compared to normal controls.
SPEAKER_00So some regions are turning the volume way up and others are going quiet.
SPEAKER_01Exactly. It indicates an altered network configuration. The brain is likely rerouting processing power, attempting another layer of functional compensation before the network eventually disintegrates in the later stages of the disease.
SPEAKER_00It's rewiring itself to survive.
SPEAKER_01Yes. Furthermore, a study by Q et al. revealed lower functional connectivity specifically between the left hippocampus and the right thalamus in the IBJ S C D group.
SPEAKER_00The thalamus. That's basically the brain's main relay station, right?
SPEAKER_01Yes, it relays sensory and motor signals. And the fMRI shows that the communication bridge between the memory center of the hippocampus and the relay station is beginning to fray.
SPEAKER_00Long before the memory itself completely fails.
Diabetes And Accelerated Decline
SPEAKER_01Exactly. The bridge is weakening before it collapses.
SPEAKER_00Okay, let's just take a breath and consolidate what we have so far because it is a lot.
SPEAKER_01It's a mountain of data.
SPEAKER_00We have mathematical proof from the process scores that the brain is struggling. We have structural MRI proof that the internal gateway is thinning. We have PEAT scans showing plaques building. We have arterial spin labeling showing the blood flow revving to compensate, and fMRI showing the network rewiring itself.
SPEAKER_01The evidence is just overwhelming.
SPEAKER_00It is a meticulously documented biological reality. But here's the massive real-world problem.
SPEAKER_01The logistics.
SPEAKER_00Exactly. Getting an MRI or a PEET scam is wildly expensive. It takes months to schedule, it requires a specialized facility, and it is rarely covered by insurance for just preliminary screening.
SPEAKER_01It's a huge bottleneck in the medical system.
SPEAKER_00So the holy grail of Alzheimer's research has always been the chemical trail. Can we detect these objects SCD changes in blood or spinal fluid? Can we just find a simple test?
SPEAKER_01We can, and this is where the research leaps from theoretical neuroscience into highly actionable clinical practice.
SPEAKER_00Awesome. Let's hear it.
SPEAKER_01The review explores several key fluid biomarkers. Let's start with plasma PTL 181.
SPEAKER_00Okay, we talked about tau earlier, the protein that tangles inside the cell. What does the P stand for and what does 181 mean? Let's really break down the mechanics here.
SPEAKER_01Sure. So the P stands for phosphorylated. Through normal biological processes, enzymes add a phosphate group to the tau protein.
SPEAKER_00I gotta ask, what does adding a phosphate actually do to the protein? I'm not a biochemist.
SPEAKER_01Right. Think of a phosphate group, like a tiny heavy magnet attaching itself to the tau protein. It actually changes the protein's electrical charge and its physical shape.
SPEAKER_00Oh, interesting.
SPEAKER_01When too many phosphate groups attach, which is called hyperphosphorylation, the tau protein loses its grip on those microtubule tracts inside the neuron.
SPEAKER_00It falls off the track.
SPEAKER_01It falls off, it changes shape, and it becomes incredibly sticky, clumping together with other tau proteins to form those lethal tangles we talked about.
SPEAKER_00Okay, and the 181 part.
SPEAKER_01The 181 simply refers to the specific spot, the 181st amino acid on the protein chain where that phosphate magnet is attached.
SPEAKER_00Got it. So it's an exact address on the protein.
SPEAKER_01Yes. And it turns out that PTO 181 is a highly specific marker for Alzheimer's disease progression, and as the neurons die, it leaks out of the brain and into the bloodstream.
SPEAKER_00So the Thomas Edel study looked at the levels of this sticky PAL 181 in the blood of Obj SCD patients. What did they find? Were the levels just sky high right away?
SPEAKER_01No. And that is what makes the finding so nuanced and important.
SPEAKER_00Yeah.
SPEAKER_01If you took a single baseline snapshot on day one, the obj SED group had levels of plasma PTA-181 that looked relatively normal.
SPEAKER_00Really? Practically indistinguishable from the healthy control group.
SPEAKER_01Yes.
SPEAKER_00So a simple one-off blood test at a physical wouldn't actually catch them.
SPEAKER_01Correct. Not at a single point in time. But when they looked longitudinally over a four-year period, the narrative completely changed.
SPEAKER_00What happened?
SPEAKER_01The individuals classified with obj S C D exhibited the absolute steepest increase in PTAW 181 levels over that time frame compared to any other group.
SPEAKER_00It's not about the total amount, it's about the velocity of the change.
SPEAKER_01Exactly. The rate of accumulation was skyrocketing. Precisely. And to take that a step further, the researchers found that if an individual is classified as of JSTD and they were positive for amyloid plaques on a PT scan.
SPEAKER_00That specific combination must be bad news.
SPEAKER_01Very bad. That combination predicted the absolute fastest rate of subsequent cognitive and functional decline.
SPEAKER_00It's a deadly synergistic combo. Okay, so that's blood. What about testing the spinal fluid? The source mentions a marker called GAP43. What is that?
SPEAKER_01So GAP43 is a protein that is heavily concentrated in the synapses.
SPEAKER_00The synapses being the gaps between the neurons.
SPEAKER_01Right, the microscopic gaps where two neurons connect and communicate chemically. GAP43 is vital for synaptic plasticity and regeneration.
SPEAKER_00So how does it become a biomarker? For cognitive decline.
SPEAKER_01Well, when synapses are put under immense coxic stress from the amyloid and tau we've been talking about, they begin to malfunction and eventually they rupture.
SPEAKER_00Like a wire snapping.
SPEAKER_01Yes. And when a synapse breaks down, it spills its contents, including that GAP43, directly into the cerebrospinal fluid.
SPEAKER_00So elevated GAP43 is a direct chemical signal of synaptic dysfunction. And how did that correlate with the UBJ SCD group?
SPEAKER_01A study by Gonzalez et al. demonstrated that if a patient had obj SCD and was amyloid positive, having a higher baseline level of GAP-43 in their spinal fluid strongly predicted a much faster rate of functional decline over the next four years.
SPEAKER_00Wow. It provides chemical proof that the physical connections, the synapses themselves, are actively snapping and misfiring during the obj SCD phase, well before a clinical MCI diagnosis is ever made.
SPEAKER_01The physical cables are sparking and shorting out. You can measure it.
SPEAKER_00Is there another blood marker that tracks this kind of structural damage?
SPEAKER_01Yes, there's plasma NFL, which stands for neurofilament light chain.
SPEAKER_00Walk us through what NFL is structurally. What does it do in the brain?
SPEAKER_01Imagine the axon of a neuron, the long cable that sends electrical signals out like a long suspension bridge.
SPEAKER_00Okay, suspension bridge.
SPEAKER_01Neurofilaments are the rigid internal steel scaffolding that gives that bridge its shape and structural integrity.
SPEAKER_00So if I'm testing the blood for it.
SPEAKER_01If you see pieces of that steel scaffolding floating downstream in the river, the bloodstream, you know definitively that a bridge has collapsed upstream.
SPEAKER_00Oh, that's a great analogy.
SPEAKER_01When brain cells are injured or die, regardless of the specific disease causing it, they spill their structural NFL scaffolding into the blood. It is a highly sensitive, albeit general, marker of neuronal death.
SPEAKER_00So if NFL is high, brain cells are dying point blank.
SPEAKER_01Yes.
SPEAKER_00What did the data show for UBJ SCD specifically?
SPEAKER_01The studies confirmed that baseline plasma NFL was significantly higher in the UBSCD group than in normal controls.
SPEAKER_00The steel scaffolding is already floating in the blood.
SPEAKER_01And crucially, one study highlighted that combining the blood test for PTAL 181 with the test for NFL provided a highly accurate model for discriminating early pathology from normal aging.
SPEAKER_00That makes perfect sense, right. By measuring PTAL 181, you confirm the presence of the specific Alzheimer's pathology. Right. And by measuring NFL, you confirm that this pathology is actively killing the brain cells. The combination creates this massive early warning system.
SPEAKER_01Aaron Powell It's a powerful one-two punch for diagnostics.
SPEAKER_00No, I have to stop and ask about one specific incredibly bizarre detail in the sources.
SPEAKER_01I know exactly what you're going to ask about.
SPEAKER_00It made me do a complete double take. There is a mention of testing urine for formaldehyde.
SPEAKER_01Yes, the formaldehyde anomaly.
SPEAKER_00That sounds absolutely wild. Why on earth would there be embalming fluid in the brain and does peeing it out mean I have objus CD?
SPEAKER_01It is definitely a fascinating and somewhat controversial tangent in the biomarker research. First, to answer your question about why it's there at all, formaldehyde
Imaging Proof With ATN Biomarkers
SPEAKER_01isn't just an external chemical used in morgues.
SPEAKER_00It's not.
SPEAKER_01No. It is actually produced endogenously, naturally inside the body through various metabolic processes like oxidative stress and DNA methylation.
SPEAKER_00Wow. Okay.
SPEAKER_01The brain naturally produces trace amounts of it, but in healthy aging, the body clears it out efficiently.
SPEAKER_00Okay, so it's a natural byproduct of cellular metabolism. Why did researchers start testing urine for it?
SPEAKER_01Well, the Wang et al. study investigated urine formaldehyde because previous literature had suggested that its levels might increase abnormally with age and could potentially predict cognitive impairment.
SPEAKER_00And obviously the appeal is huge. A simple urine test is infinitely more accessible and non-invasive than a spinal tap or a blood draw.
SPEAKER_01Exactly. Everyone can pee in a cup.
SPEAKER_00Did it work? Did the abjesh SCD patients have high formaldehyde?
SPEAKER_01Surprisingly, no. And this is where the data gets really messy.
SPEAKER_00Seeow.
SPEAKER_01The study found that urine formaldehyde was significantly upregulated in people with subjective cognitive decline.
SPEAKER_00Wait, the group we discussed earlier who actively complain about their memory but test normally?
SPEAKER_01Yes. But there was absolutely no difference in formaldehyde levels between the normal controls, the obj SCD group, and the MCI group.
SPEAKER_00Let me process that. The objective mathematically proven pathology groups didn't have elevated formaldehyde, but the subjective complainers did.
SPEAKER_01Correct.
SPEAKER_00That completely contradicts all the other biomarker trends we've seen, like the Tau and the amyloid data. Why would that happen?
SPEAKER_01It is puzzling, but the authors hypothesize that the formaldehyde spike might represent a highly nonlinear, incredibly early metabolic compensation mechanism.
SPEAKER_00Nonlinear, meaning it doesn't just go steadily up as the disease gets worse.
SPEAKER_01Exactly. The theory is that formaldehyde spikes extremely early on, right when the brain first encounters oxidative stress.
SPEAKER_00Okay.
SPEAKER_01And this spike might actually be what triggers the subjective feeling of fogginess or anxiety in this subjective cognitive decline group.
SPEAKER_00So the chemical spike is what's making them feel weird.
SPEAKER_01Right. But as the true heavy Alzheimer's pathology takes over in the obj, S C D and MCI stages, that specific chemical pathway might shut down or alter entirely, dropping the formaldehyde levels back down to a normal baseline, even as the Tau and amyloid continue to climb.
SPEAKER_00Wow. It's a humbling reminder that human biology is just chaotic. It doesn't always follow a clean, straight line on a graph. Not at all. Okay, let's step back and survey the landscape. The science we've unpacked today is incredibly rigorous. We have actuarial math accurately predicting decline based on subtle process errors. We have MRIs showing the interhinal cortex thinning and blood flow revving to compensate.
SPEAKER_01We have blood tests tracking the exact velocity of toxic protein accumulation.
SPEAKER_00Right. So the obvious screaming question is: why isn't this standard practice right now? If I go to my doctor tomorrow for an annual physical and I'm 55 years old, why aren't they screening me for a JSCD?
SPEAKER_01That is the multi-billion dollar question that health systems around the world are currently grappling with.
SPEAKER_00Why hold up?
SPEAKER_01The review meticulously outlines several massive real-world barriers that are currently trapping this science in the research lab and keeping it out of your local clinic.
SPEAKER_00Let's walk through those walls. Barrier number one has to be the sheer logistics and cost of the diagnosis, right?
SPEAKER_01Absolutely. Think about what is practically required to obtain an obj SCD diagnosis based on the Edmonds and Thomas criteria we discussed.
SPEAKER_00It's not simple.
SPEAKER_01No, you can't just take a quick online quiz. You require a comprehensive, formal, neuropsychological evaluation. That means you need to sit in a quiet room with a highly trained, specialized clinical neuropsychologist for anywhere from two to four hours.
SPEAKER_00Four hours. Taking batteries of complex, exhausting tests like the Ray AVLT, just so they can manually calculate your specific process scores and intrusion errors.
SPEAKER_01Right, and then they have to cross-reference your specific scores against massive age and education adjusted normative databases. Those evaluations are incredibly expensive. I can imagine. They run into the thousands of dollars. Furthermore, they are rarely covered by standard insurance unless a patient already exhibits severe, undeniable cognitive problems.
SPEAKER_00Which completely defeats the purpose of early detection.
SPEAKER_01Exactly. On top of the financial costs, there is a massive global shortage of clinical neuropsychologists. It is logistically and economically impossible to give every 50-year-old on the planet a three-hour cognitive exam. The system would collapse overnight.
SPEAKER_00So it's just not scalable at all right now. Okay, barrier two. What about the human element, the patients themselves?
SPEAKER_01There is a profound fundamental lack of motivation for patients to seek this diagnosis out. Remember the data on subjective memory complaints? The SMC negative group. Exactly. The target demographic for an obj SCD screening are people who are generally much younger than the typical age of dementia onset. They are in their 50s or early 60s. Right. They are at the peak of their careers, they're paying mortgages, they are raising teenagers or helping aging parents. They do not feel impaired.
SPEAKER_00Yeah, why would they go to the doctor?
SPEAKER_01There's absolutely no internal motivation for them to voluntarily take a day off work to subject themselves to a grueling, expensive, multi-hour cognitive exam that might tell them they are slowly developing a terminal neurological disease.
SPEAKER_00The psychological burden of knowing is massive. If you feel fine, why go looking for a ghost?
SPEAKER_01Exactly. And that leads directly into the third major medical barrier: diagnostic heterogeneity.
SPEAKER_00Diagnostic heterogeneity, meaning the diagnosis isn't a silver bullet.
SPEAKER_01Exactly. Subtle cognitive decline is just that subtle. Yes, failing those process scores could be the very early whispers of Alzheimer's disease. But it could also be a dozen other things.
SPEAKER_00Like what what else causes you to fail a memory process score?
SPEAKER_01It
Complaints Versus Plaques And Insight Loss
SPEAKER_01could be the early stages of Parkinson's disease or Lewy body dementia. It could be microvascular damage caused by years of unmanaged hypertension. Oh wow. It could be severe chronic sleep apnea depriving the brain of oxygen every night. It could be intense psychological stress, severe depression, or even just a severe B12 vitamin deficiency.
SPEAKER_00So failing the process scores tells you the engine is checking out and the AC is blasting at 110%, but it doesn't guarantee the engine is failing specifically because of Alzheimer's.
SPEAKER_01Precisely. Up GSCD is a phenomenal, highly sensitive net for catching people whose brains are under stress. But that net catches a lot of different things.
SPEAKER_00So you still need more tests.
SPEAKER_01Right. To figure out why the cognitive decline is happening, the doctor still has to order the expensive invasive biomarker tests, the PET scans for amyloid, or the spinal caps for Tau. The cognitive test alone isn't enough to prescribe a disease-modifying Alzheimer's drug.
SPEAKER_00So if those are the massive towering walls blocking clinical implementation, what are the future directions? How does the medical field actually use this research to help people in the next five or ten years?
SPEAKER_01The future lies in simplifying and democratizing the diagnostic funnel. The review points heavily toward the rapidly advancing role of new plasma biomarkers, specifically a marker called plasma PTA 217.
SPEAKER_00Wait, we talked about Pita 181 earlier. How is PTA 217 different?
SPEAKER_01It's another phosphorylated form of tau, but the research suggests it is even more exquisitely sensitive and specific to Alzheimer's pathology than 181.
SPEAKER_00Okay, so it's a better magnet.
SPEAKER_01Exactly. Its levels seem to increase progressively and reliably along the entire disease continuum, from the earliest silent stages all the way to full dementia. In fact, this is moving so fast that the FDA recently approved the use of a specific blood test ratio comparing PETA 217 to a specific amyloid beta fragment as a diagnostic tool.
SPEAKER_00A simple blood test. That changes the entire logistical equation.
SPEAKER_01Yes, it really does. The clinical vision for the near future is a combined, highly accessible model.
SPEAKER_00What does that look like?
SPEAKER_01Well, you wouldn't start your journey with a three-hour, three thousand dollar neuropsychological exam. Instead, at your standard annual physical, your primary care doctor would just draw your blood and run the PETA 217 panel.
SPEAKER_00Along with your cholesterol and everything else.
SPEAKER_01Exactly. And while you wait, they might hand you an iPad with a highly calibrated 10-minute digital cognitive test.
SPEAKER_00And the software automatically runs the actuarial math, instantly calculating process errors and intrusion rates.
SPEAKER_01Exactly. If that simple, cheap 10-minute screening raises a red flag, if your blood shows the toxic protein and the iPad flags, a process error, then and only then do you get referred to the specialist for the expensive in-depth of JSCD evaluation and the PE scans to confirm the pathology.
SPEAKER_00That tiered approach makes early detection financially and logistically scalable for the global population.
SPEAKER_01Yes.
SPEAKER_00But the review also mentions a massive flashing warning sign for all of this future technology, right? We touched on it earlier, but it is the data problem.
SPEAKER_01Yes, and I cannot stress this enough. The absolute necessity to expand research beyond the homogeneous ABI database is paramount.
SPEAKER_00Because if we build the future of Alzheimer screening the algorithms on that iPad, the cutoff levels for that blood test, based entirely on a mathematical model derived from highly educated, predominantly white populations, we are going to fail everyone else.
SPEAKER_01We will generate massive amounts of false positives and false negatives in minority populations.
SPEAKER_00Which is unacceptable.
SPEAKER_01The algorithms and the mathematical thresholds for objus A C D must be rigorously validated across diverse races, ethnicities, different primary languages, and drastically different educational levels.
SPEAKER_00Aaron Powell Right. A process error for a bilingual patient with a high school education might look mathematically completely different than a process error for a monolingual patient with a doctorate.
SPEAKER_01Exactly. If we don't account for that, the diagnostic criteria will not be equitable.
SPEAKER_00And if the math is going to determine who gets access to life-altering disease-modifying medication, the math has to be impeccably accurate for every human being on the planet.
SPEAKER_01Precisely. The science must serve the entirety of the population.
SPEAKER_00Okay, let's step back and synthesize this incredible journey we've been on. We started this deep dive looking at a medical landscape where Alzheimer's was treated basically like a broken bone. You either had dementia or you didn't.
SPEAKER_01You waited until the house was fully engulfed in flames before you cold the fire department.
SPEAKER_00Exactly. And we have moved to a world where, through the lens of objectively defined subtle cognitive decline, we can now smell the smoke decades in advance.
SPEAKER_01It's a true paradigm shift.
SPEAKER_00We can measure that smoke in how your brain accidentally invents a word on a memory test. We can physically see it and how your neurovascular system frantically pumps extra blood to your hippocampus, blasting the AC to keep the room cool.
SPEAKER_01We can chemically track it and the tau proteins and the snap to synaptic cables silently pooling in your final flute long before you ever realize you were slipping.
SPEAKER_00So Ubjace SCD isn't just a new medical acronym for doctors to memorize. It is a massive structural leap forward in human health.
SPEAKER_01It allows us to mathematically isolate the at-risk population precisely at the fragile moment when these new disease-modifying drugs can actually do their job, protecting the structural integrity of the brain before the memory center physically collapses.
SPEAKER_00It redefines the timeline of human aging and medical intervention, but it also leaves us with something deeply personal and frankly deeply uncomfortable to consider. Because we are rapidly approaching a reality where a simple blood test at your standard physical, combined with a quick 10-minute puzzle on an iPad, could tell you with chilling mathematical accuracy that your brain is on the path to Alzheimer's decades before you forget a single name. The question for you, the
Where Damage Starts In The Brain
SPEAKER_00listener, is this if that test becomes available at your doctor's office next year, do you want to know the answer?
SPEAKER_01That's the heavy question.
SPEAKER_00It really is. Thank you for taking this deep dive with us today. You are now armed with the knowledge of the absolute frontier of neurological science. Keep questioning the consensus, keep exploring the data, and we will catch you on the next deep dive.